CERC-007 is a fully human anti-IL-18 monoclonal antibody with the potential to address multiple auto-inflammatory diseases, including Multiple Myeloma (MM) and Adult Onset Still's Disease (AOSD). IL-18 is a pro-inflammatory cytokine; patients with MM and AOSD show elevated levels of IL-18. Cerecor seeks to initiate a Phase 1b/2a proof-of-concept study of CERC-007 in MM and AOSD and patients in 2020


Targeting Multiple Myeloma

Multiple Myeloma - Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Plasma cells help you fight infections by making antibodies that recognize and attack germs.  Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells. Rather than produce helpful antibodies, the cancer cells produce abnormal proteins that can cause complications.

of CERC-007

  • Fully human, high affinity, neutralizing monoclonal antibody against IL-18
  • Evaluated in Phase 1 study; safe and well-tolerated up to 1000 mg with IL-18 knockdown out to 3 months following single dose
  • Potential for biomarker-driven clinical development approach for patient selection and dose titration